JPMorgan Chase & Co. Has $269,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

JPMorgan Chase & Co. cut its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 80.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,500 shares of the company’s stock after selling 319,533 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.08% of Aquestive Therapeutics worth $269,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the business. New York State Common Retirement Fund increased its position in shares of Aquestive Therapeutics by 713.3% in the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after acquiring an additional 10,700 shares during the last quarter. PKS Advisory Services LLC acquired a new position in shares of Aquestive Therapeutics during the 4th quarter worth approximately $63,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aquestive Therapeutics during the 4th quarter worth approximately $69,000. SBI Securities Co. Ltd. bought a new stake in shares of Aquestive Therapeutics during the 4th quarter worth approximately $115,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Aquestive Therapeutics by 28.7% in the 4th quarter. SG Americas Securities LLC now owns 32,966 shares of the company’s stock valued at $117,000 after buying an additional 7,347 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Performance

NASDAQ AQST opened at $3.00 on Friday. Aquestive Therapeutics, Inc. has a 52-week low of $2.20 and a 52-week high of $5.80. The stock has a market cap of $296.61 million, a PE ratio of -6.67 and a beta of 2.59. The firm has a 50-day moving average of $2.78 and a 200-day moving average of $3.56.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The business had revenue of $11.87 million for the quarter, compared to analysts’ expectations of $13.11 million. As a group, analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on AQST shares. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital lowered their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Wednesday, April 2nd. Finally, Raymond James set a $7.00 price target on Aquestive Therapeutics in a report on Friday, March 7th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $10.67.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.